Teledermatology Direct-to-Surgery Pathway Delivers Fast Skin Cancer Triage in NHS Service
Teledermatology is no longer just a screening convenience for busy skin clinics. In a large NHS service evaluation from University Hospitals of North Midlands, a direct-to-surgery pathway moved selected patients with suspected skin cancer from referral to biopsy or excision without a preliminary face-to-face consultation, and the model performed with striking speed. Among 5099 included patients, compliance with the 28-day Faster Diagnosis Standard reached 99.86%, far above the national target of 75%.
The practical appeal is obvious at the bedside and in the booking office alike. When image-based triage can safely separate straightforward lesions from those that need immediate tissue diagnosis, the whole pathway compresses: fewer outpatient visits, faster histology, and less time spent waiting while a lesion remains unclassified.
Referral Volume, Surgical Throughput, and Time to Diagnosis
The evaluation covered teledermatology referrals received between February 2022 and July 2024. Of 18,587 referrals, 5120 were triaged into the direct-to-surgery arm. After removal of 20 miscoded entries and one duplicate record, 5099 patients remained for analysis. A total of 4830 patients proceeded to surgery, and 4825 obtained definitive histopathological diagnoses.
Median time from referral to histology reporting was 46 days. In a service built around suspected skin cancer, that interval matters because lesion biology does not pause for clinic logistics. Melanoma and squamous cell carcinoma can progress during delays, and a workflow that keeps the diagnostic chain moving can reduce the window between suspicion and confirmation.
A single sentence captures the operational gain. The pathway converted a very large referral stream into near-universal compliance with the national diagnostic standard.
Cancer Yield and What Histology Revealed About Risk Stratification
Histopathology showed malignant pathology in 35.5% of lesions and premalignant pathology in another 15.5%. Those proportions suggest the triage model was handling a mixed but meaningful-risk population, not simply low-acuity dermatology traffic. For services under pressure, that is where teledermatology becomes more than a convenience; it becomes a triage mechanism that channels surgical capacity toward lesions with real oncologic consequence.
The abstract does not provide lesion-level clinicopathologic detail, and it should not be overread beyond the data presented. Even so, the histology yield indicates that many patients arriving on the direct-to-surgery route already had lesions with enough suspicion to justify immediate tissue sampling rather than a staged consultation process. That kind of workflow depends on image quality, referral selection, and clinician judgment at triage. When those pieces align, face-to-face assessment can be reserved for the subgroup in whom morphology, history, or distribution makes the diagnosis less certain.
Diagnostic Concordance Remained Modest Despite Excellent Workflow Performance
Diagnostic concordance between teledermatology assessment and final histology was not high. Among lesions with both a recorded teledermatology diagnosis and definitive histology, overall concordance was 41.5% (1113/2679), with fair agreement by Cohen’s κ of 0.34. This is the key interpretive tension in the study: a pathway can be highly efficient without being highly precise in categorical diagnosis.
That pattern is not surprising in skin cancer triage. Image-based assessment can identify lesions that need rapid tissue diagnosis, but visual classification alone is often less reliable when actinic damage, pigmented lesions, inflammatory mimics, or subtle morphology blur the line between benign and malignant appearances. The modest κ value suggests teledermatology worked best as a risk-stratification tool rather than a substitute for histopathologic diagnosis.
Safety Signals Stayed Low Across a High-Volume Surgical Pathway
The overall complication rate was 1.3%. In a model designed to accelerate surgery, that low rate is clinically important because speed would be unacceptable if it came at the cost of avoidable harm. Here, the pathway maintained safety while handling a large referral load and avoiding a preliminary in-person assessment for selected patients.
Low complication rates also support the logic of direct-to-surgery triage. If the triage step can identify lesions that are suitable for immediate biopsy or excision, the service can move decisively without introducing excess procedural risk. The dataset does not specify the complication types in the abstract, so no finer-grained safety interpretation is possible here. Still, the aggregate rate is reassuring in a setting where clinicians may worry that bypassing a face-to-face consultation could miss surgical complexity.
Missed Opportunity or Efficient Filtering? The Data Favor the Latter
Among patients diagnosed with melanoma or squamous cell carcinoma, 75.5% (440/583) started treatment within the 62-day referral-to-treatment target. That figure is not identical to the faster diagnostic metric, and the gap reflects the reality that diagnosis and treatment are related but not interchangeable stages of care. Some lesions will require more extensive planning, reconstruction, or multidisciplinary coordination after histology returns.
Even so, the treatment metric shows that the pathway did more than accelerate pathology reporting. It helped move a large malignant subset into the therapeutic phase within the expected national window. For a skin cancer service, that is the operational payoff: less administrative drag, more direct movement from referral to definitive management, and a narrower interval in which cancer can sit untreated.
What This NHS Model Means for Skin Cancer Services
This single-centre evaluation supports direct-to-surgery teledermatology as a workable model for high-volume skin cancer services. It achieved exceptional compliance with the 28-day Faster Diagnosis Standard, kept the complication rate low, and handled a substantial surgical workload while preserving access to histology. The performance is particularly relevant for NHS systems trying to absorb growing referral volumes without adding a parallel layer of clinic visits.
The data also keep expectations grounded. Diagnostic concordance was only fair, which means teledermatology should be understood as a triage instrument rather than a definitive classifier. The pathway succeeds when the aim is to identify lesions that should move quickly to tissue diagnosis, not when it is asked to replace pathology or the judgment that follows a physical examination in more ambiguous cases.
A larger multicentre assessment would be needed to know how generalizable these results are across different referral patterns, imaging standards, and surgical teams. For now, the study shows that when teledermatology is paired with a direct-to-surgery pathway, the system can move quickly, stay safe, and reach the people who most need histologic confirmation without delay.